Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C10H17N3O6S |
Molecular Weight | 307.325 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C(CC(=N[C@@]([H])(CS)C(=NCC(=O)O)O)O)[C@@]([H])(C(=O)O)N
InChI
InChIKey=RWSXRVCMGQZWBV-WDSKDSINSA-N
InChI=1S/C10H17N3O6S/c11-5(10(18)19)1-2-7(14)13-6(4-20)9(17)12-3-8(15)16/h5-6,20H,1-4,11H2,(H,12,17)(H,13,14)(H,15,16)(H,18,19)/t5-,6-/m0/s1
Molecular Formula | C10H17N3O6S |
Molecular Weight | 307.325 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment:: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23036594 |
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ef475c9-7938-4870-b336-fb0c2dafb3cd | https://clinicaltrials.gov/ct2/show/NCT01450267
Curator's Comment:: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23036594 |
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ef475c9-7938-4870-b336-fb0c2dafb3cd | https://clinicaltrials.gov/ct2/show/NCT01450267
Glutathione (GSH, also called as reduced glutathione) is a tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes such as, glutathione reductase, glutathione peroxidases, peroxiredoxins. Glutathione S-transferases catalyse the conjugation of GSH via a sulfhydryl group to electrophilic centers on a wide variety of substrates in order to make the compounds more water-soluble. As a part of homeopathic product, glutathione is used for temporary relief of symptoms related to Free Radical Toxicity including tingling in hands and feet, mood changes, frequent colds, poor digestion, fatigue, and constipation. In addition, for temporary relief of pain in the back from urinating, constant urging and frequent urination, kidneys sensitive to pressure, and pain from back extending down the thigh. Glutathione is an important nutrient for brain function and loss of glutathione has been implicated in Parkinson's disease. In phase II of the clinical trial was investigated whether administration of either dose of glutathione, as a nasal spray, improves PD symptoms over time in a population of individuals with Parkinson's disease (PD). In addition in phase II of clinical trial was shown, that reduced glutathione, an ingredient of RayGel™, has been helpful in decreasing some radiation therapy side effects to the skin. Reduced glutathione plays a vital role in both making DNA and cell repair. Cystic fibrosis (CF) is the most common inherited disease among the Caucasian population with considerable morbidity and reduced life expectancy. Glutathione (GSH) represents the first-line defence of the lung against oxidative stress-induced cell injury. Therapeutic approaches with inhaled GSH could improve the reduced lung antioxidant capacity in order to counterbalance the oxidant stress linked to the chronic airway inflammation and bacterial infection.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Glutathione S-transferases Sources: https://www.ncbi.nlm.nih.gov/pubmed/4436301 |
|||
Target ID: P00390 Gene ID: 2936.0 Gene Symbol: GSR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/23036594 |
|||
Target ID: Glutathione peroxidases Sources: https://www.ncbi.nlm.nih.gov/pubmed/23036594 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Synergistic effect of diesel organic extracts and allergen Der p 1 on the release of chemokines by peripheral blood mononuclear cells from allergic subjects: involvement of the map kinase pathway. | 2000 Aug |
|
The protective effect of glutathione administration on adriamycin-induced acute cardiac toxicity in rats. | 2000 Aug |
|
Apoptosis induced by extracellular glutathione is mediated by H(2)O(2) production and DNA damage. | 2000 Aug 1 |
|
A lens glutathione S-transferase, class mu, with thiol-specific antioxidant activity. | 2000 Sep |
|
Assays for mitogen-activated protein kinase (MAPK) subtypes and MAPK activating protein kinase-2 (MAPKAP K-2) using a common cell lysate. | 2001 |
|
Direct interaction between endothelial nitric-oxide synthase and dynamin-2. Implications for nitric-oxide synthase function. | 2001 Apr 27 |
|
Nitrogen monoxide (no) and glucose: unexpected links between energy metabolism and no-mediated iron mobilization from cells. | 2001 Feb 16 |
|
Glutathiolation of proteins by glutathione disulfide S-oxide derived from S-nitrosoglutathione. Modifications of rat brain neurogranin/RC3 and neuromodulin/GAP-43. | 2001 Feb 2 |
|
The glutathione transferase structural family includes a nuclear chloride channel and a ryanodine receptor calcium release channel modulator. | 2001 Feb 2 |
|
The kinetic mechanism of the dual phosphorylation of the ATF2 transcription factor by p38 mitogen-activated protein (MAP) kinase alpha. Implications for signal/response profiles of MAP kinase pathways. | 2001 Feb 23 |
|
Human glutathione transferase T2-2 discloses some evolutionary strategies for optimization of substrate binding to the active site of glutathione transferases. | 2001 Feb 23 |
|
Human glutathione transferase T2-2 discloses some evolutionary strategies for optimization of the catalytic activity of glutathione transferases. | 2001 Feb 23 |
|
Cloning, expression, and up-regulation of inducible rat prostaglandin e synthase during lipopolysaccharide-induced pyresis and adjuvant-induced arthritis. | 2001 Feb 9 |
|
High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. | 2001 Jan |
|
Effects of phenytoin on glutathione status and oxidative stress biomarker gene mRNA levels in cultured precision human liver slices. | 2001 Jan |
|
The activity of NF-kappaB in Swiss 3T3 cells exposed to aqueous extracts of cigarette smoke is dependent on thioredoxin. | 2001 Jan |
|
Ochratoxin A-induced tumor formation: is there a role of reactive ochratoxin A metabolites? | 2001 Jan |
|
Dual effects of nitric oxide in functional and regressing rat corpus luteum. | 2001 Jan |
|
Major changes in human ocular UV protection with age. | 2001 Jan |
|
Oxidative stress and antioxidant defenses in goldfish Carassius auratus during anoxia and reoxygenation. | 2001 Jan |
|
Overcoming drug resistance in ovarian carcinoma. | 2001 Jan |
|
Homocysteine and thiol metabolites in vitamin B12 deficiency. | 2001 Jan |
|
Genomic organization and putative promoters of highly conserved glutathione S-transferases originating by alternative splicing in Anopheles dirus. | 2001 Jan |
|
Single amino acid changes outside the active site significantly affect activity of glutathione S-transferases. | 2001 Jan |
|
The intracellular oxidation of 2',7'-dichlorofluorescin in murine T lymphocytes. | 2001 Jan 1 |
|
Thiols can either enhance or suppress DNA damage induction by catecholestrogens. | 2001 Jan 1 |
|
Superoxide radical-initiated apoptotic signalling pathway in selenite-treated HepG(2) cells: mitochondria serve as the main target. | 2001 Jan 1 |
|
Differential effects of bcl-2 on cell death triggered under ATP-depleting conditions. | 2001 Jan 1 |
|
Evidence for the presence of phospholipid hydroperoxide glutathione peroxidase in human platelets: implications for its involvement in the regulatory network of the 12-lipoxygenase pathway of arachidonic acid metabolism. | 2001 Jan 1 |
|
Tamoxifen mutagenesis and carcinogenesis in livers of lambda/lacI transgenic rats: selective influence of phenobarbital promotion. | 2001 Jan 10 |
|
Synergistic enhancement of nuclear receptor function by p160 coactivators and two coactivators with protein methyltransferase activities. | 2001 Jan 12 |
|
Affinity labeling of rat glutathione S-transferase isozyme 1-1 by 17beta -iodoacetoxy-estradiol-3-sulfate. | 2001 Jan 19 |
|
2-acetylaminofluorene up-regulates rat mdr1b expression through generating reactive oxygen species that activate NF-kappa B pathway. | 2001 Jan 5 |
|
Eosinophil peroxidase oxidation of thiocyanate. Characterization of major reaction products and a potential sulfhydryl-targeted cytotoxicity system. | 2001 Jan 5 |
|
Inhibition of adenylate cyclase activity by 5-aminolevulinic acid in rat and human brain. | 2001 Mar |
|
Role of multidrug resistance protein 1 (MRP1) and glutathione S-transferase A1-1 in alkylating agent resistance. Kinetics of glutathione conjugate formation and efflux govern differential cellular sensitivity to chlorambucil versus melphalan toxicity. | 2001 Mar 16 |
|
Characterization of transsulfuration and cysteine biosynthetic pathways in the protozoan hemoflagellate, Trypanosoma cruzi. Isolation and molecular characterization of cystathionine beta-synthase and serine acetyltransferase from Trypanosoma. | 2001 Mar 2 |
|
WD repeat domains target dictyostelium myosin heavy chain kinases by binding directly to myosin filaments. | 2001 Mar 2 |
|
Glutathione stimulates sulfated estrogen transport by multidrug resistance protein 1. | 2001 Mar 2 |
|
The cytosolic O-acetylserine(thiol)lyase gene is regulated by heavy metals and can function in cadmium tolerance. | 2001 Mar 23 |
|
Interaction of the type IIa Na/Pi cotransporter with PDZ proteins. | 2001 Mar 23 |
|
Structural properties and mechanisms that govern association of C kinase adapter 1 with protein kinase C3 and the cell periphery. | 2001 Mar 30 |
|
Carbon dioxide stimulates the production of thiyl, sulfinyl, and disulfide radical anion from thiol oxidation by peroxynitrite. | 2001 Mar 30 |
|
Phosphorylation of tau is regulated by PKN. | 2001 Mar 30 |
|
Interaction with p53 enhances binding of cisplatin-modified DNA by high mobility group 1 protein. | 2001 Mar 9 |
|
Protein kinase C activation modulates alpha-calmodulin kinase II binding to NR2A subunit of N-methyl-D-aspartate receptor complex. | 2001 Mar 9 |
|
Zinc release from the CH2C6 zinc finger domain of FILAMENTOUS FLOWER protein from Arabidopsis thaliana induces self-assembly. | 2001 Mar 9 |
|
The putative glutathione peroxidase gene of Plasmodium falciparum codes for a thioredoxin peroxidase. | 2001 Mar 9 |
|
Novel G proteins, Rag C and Rag D, interact with GTP-binding proteins, Rag A and Rag B. | 2001 Mar 9 |
|
Expression-independent consumption of substrates in cell-free expression system from Escherichia coli. | 2001 Nov 17 |
Patents
Sample Use Guides
For temporary relief of symptoms related to Free Radical Toxicity: 1-10 drops under the tongue, 3 times a day or as directed by a health professional. Consult a physician for use in children under 12 years of age.
pain in the back from urinating: 10 drops orally, 3 times a day. Consult a physician for use in children under 12 years of age.
Breast Cancer: RayGel Topical Cream applied in thin layer to the area exposed to radiation 60-90 minutes prior to radiotherapy, standard skin care between treatments.
Cystic Fibrosis: Inhaled Reduced Glutathione 10 mg/kg, twice daily, 12 months
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 21:15:01 UTC 2021
by
admin
on
Fri Jun 25 21:15:01 UTC 2021
|
Record UNII |
GAN16C9B8O
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
57005-1
Created by
admin on Fri Jun 25 21:15:01 UTC 2021 , Edited by admin on Fri Jun 25 21:15:01 UTC 2021
|
||
|
FDA ORPHAN DRUG |
303410
Created by
admin on Fri Jun 25 21:15:01 UTC 2021 , Edited by admin on Fri Jun 25 21:15:01 UTC 2021
|
||
|
LOINC |
91685-8
Created by
admin on Fri Jun 25 21:15:01 UTC 2021 , Edited by admin on Fri Jun 25 21:15:01 UTC 2021
|
||
|
DSLD |
1621 (Number of products:627)
Created by
admin on Fri Jun 25 21:15:01 UTC 2021 , Edited by admin on Fri Jun 25 21:15:01 UTC 2021
|
||
|
WHO-VATC |
QV03AB32
Created by
admin on Fri Jun 25 21:15:01 UTC 2021 , Edited by admin on Fri Jun 25 21:15:01 UTC 2021
|
||
|
FDA ORPHAN DRUG |
77493
Created by
admin on Fri Jun 25 21:15:01 UTC 2021 , Edited by admin on Fri Jun 25 21:15:01 UTC 2021
|
||
|
LOINC |
16918-5
Created by
admin on Fri Jun 25 21:15:01 UTC 2021 , Edited by admin on Fri Jun 25 21:15:01 UTC 2021
|
||
|
LOINC |
65363-4
Created by
admin on Fri Jun 25 21:15:01 UTC 2021 , Edited by admin on Fri Jun 25 21:15:01 UTC 2021
|
||
|
FDA ORPHAN DRUG |
545816
Created by
admin on Fri Jun 25 21:15:01 UTC 2021 , Edited by admin on Fri Jun 25 21:15:01 UTC 2021
|
||
|
NCI_THESAURUS |
C275
Created by
admin on Fri Jun 25 21:15:01 UTC 2021 , Edited by admin on Fri Jun 25 21:15:01 UTC 2021
|
||
|
FDA ORPHAN DRUG |
311910
Created by
admin on Fri Jun 25 21:15:01 UTC 2021 , Edited by admin on Fri Jun 25 21:15:01 UTC 2021
|
||
|
CFR |
21 CFR 862.1365
Created by
admin on Fri Jun 25 21:15:01 UTC 2021 , Edited by admin on Fri Jun 25 21:15:01 UTC 2021
|
||
|
FDA ORPHAN DRUG |
519216
Created by
admin on Fri Jun 25 21:15:01 UTC 2021 , Edited by admin on Fri Jun 25 21:15:01 UTC 2021
|
||
|
EU-Orphan Drug |
EU/3/06/361
Created by
admin on Fri Jun 25 21:15:01 UTC 2021 , Edited by admin on Fri Jun 25 21:15:01 UTC 2021
|
||
|
DSLD |
178 (Number of products:20)
Created by
admin on Fri Jun 25 21:15:01 UTC 2021 , Edited by admin on Fri Jun 25 21:15:01 UTC 2021
|
||
|
WHO-ATC |
V03AB32
Created by
admin on Fri Jun 25 21:15:01 UTC 2021 , Edited by admin on Fri Jun 25 21:15:01 UTC 2021
|
||
|
LOINC |
2383-8
Created by
admin on Fri Jun 25 21:15:01 UTC 2021 , Edited by admin on Fri Jun 25 21:15:01 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
GLUTATHIONE
Created by
admin on Fri Jun 25 21:15:01 UTC 2021 , Edited by admin on Fri Jun 25 21:15:01 UTC 2021
|
PRIMARY | |||
|
70-18-8
Created by
admin on Fri Jun 25 21:15:01 UTC 2021 , Edited by admin on Fri Jun 25 21:15:01 UTC 2021
|
PRIMARY | |||
|
C523
Created by
admin on Fri Jun 25 21:15:01 UTC 2021 , Edited by admin on Fri Jun 25 21:15:01 UTC 2021
|
PRIMARY | |||
|
CHEMBL1543
Created by
admin on Fri Jun 25 21:15:01 UTC 2021 , Edited by admin on Fri Jun 25 21:15:01 UTC 2021
|
PRIMARY | |||
|
DB00143
Created by
admin on Fri Jun 25 21:15:01 UTC 2021 , Edited by admin on Fri Jun 25 21:15:01 UTC 2021
|
PRIMARY | |||
|
SUB13990MIG
Created by
admin on Fri Jun 25 21:15:01 UTC 2021 , Edited by admin on Fri Jun 25 21:15:01 UTC 2021
|
PRIMARY | |||
|
4890
Created by
admin on Fri Jun 25 21:15:01 UTC 2021 , Edited by admin on Fri Jun 25 21:15:01 UTC 2021
|
PRIMARY | RxNorm | ||
|
124886
Created by
admin on Fri Jun 25 21:15:01 UTC 2021 , Edited by admin on Fri Jun 25 21:15:01 UTC 2021
|
PRIMARY | |||
|
70-18-8
Created by
admin on Fri Jun 25 21:15:01 UTC 2021 , Edited by admin on Fri Jun 25 21:15:01 UTC 2021
|
PRIMARY | |||
|
1312
Created by
admin on Fri Jun 25 21:15:01 UTC 2021 , Edited by admin on Fri Jun 25 21:15:01 UTC 2021
|
PRIMARY | |||
|
M5781
Created by
admin on Fri Jun 25 21:15:01 UTC 2021 , Edited by admin on Fri Jun 25 21:15:01 UTC 2021
|
PRIMARY | Merck Index | ||
|
200-725-4
Created by
admin on Fri Jun 25 21:15:01 UTC 2021 , Edited by admin on Fri Jun 25 21:15:01 UTC 2021
|
PRIMARY | |||
|
GAN16C9B8O
Created by
admin on Fri Jun 25 21:15:01 UTC 2021 , Edited by admin on Fri Jun 25 21:15:01 UTC 2021
|
PRIMARY | |||
|
D005978
Created by
admin on Fri Jun 25 21:15:01 UTC 2021 , Edited by admin on Fri Jun 25 21:15:01 UTC 2021
|
PRIMARY | |||
|
1294820
Created by
admin on Fri Jun 25 21:15:01 UTC 2021 , Edited by admin on Fri Jun 25 21:15:01 UTC 2021
|
PRIMARY | USP-RS |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> SUBSTRATE | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
SUBSTRATE -> TARGET | |||
|
DERIVATIVE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |